1. Metabolic Enzyme/Protease
  2. Mineralocorticoid Receptor

Mineralocorticoid Receptor

Mineralocorticoid receptor (MR) is a member of the nuclear receptor superfamily and is essential for controlling sodium transport in epithelial tissues such as the kidney and colon.

Mineralocorticoid receptor (MR) is a nuclear receptor (NR) that is critical for controlling sodium and potassium transport in epithelial cells, most notably in the kidney and colon. It also plays important roles in non-epithelial tissues, such as cardiac myocytes, blood vessels, the hippocampus and adipose tissue. The MR is capable of binding multiple classes of steroids with high affinity, including the mineralocorticoids, aldosterone and deoxycorticosterone, the glucocorticoids (GR), cortisol (in humans) or corticosterone (in rodents), and progesterone (PR). While aldosterone is considered the primary physiological MR ligand in humans, in some tissues cortisol may be the primary ligand for MR, whereas PR behaves as a predominant antagonist.

Mineralocorticoid Receptor Related Products (9):

Cat. No. Product Name Effect Purity
  • HY-B0251
    Eplerenone Antagonist 99.62%
    Eplerenone is an aldosterone antagonist with an IC50 of 0.36 μM.
  • HY-B1203A
    Fludrocortisone acetate Agonist 99.45%
    Fludrocortisone Acetate is a synthetic mineralocorticoid, used to control the amount of sodium and fluids in your body.
  • HY-B1472
    Deoxycorticosterone acetate Agonist >98.0%
    Deoxycorticosterone acetate is a steroid hormone produced by the adrenal gland that possesses mineralocorticoid activity and acts as a precursor to aldosterone.
  • HY-100471
    Esaxerenone Antagonist 99.65%
    Esaxerenone is a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
  • HY-16276
    Osilodrostat Inhibitor >98.0%
    Osilodrostat (LCI699) is a potent inhibitor of human 11β-hydroxylase and aldosterone synthase with IC50 values of 2.5 and 0.7 nM, respectively.
  • HY-109002
    Apararenone Antagonist 98.80%
    Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.
  • HY-B1438
    Canrenone Antagonist 99.16%
    Canrenone (Aldadiene; SC9376; SC14266) is an aldosterone antagonist extensively used as a diuretic agent.
  • HY-B1203
    Fludrocortisone Agonist
    Fludrocortisone, a synthetic mineralocorticoid with anti-inflammatory activity.
  • HY-U00200
    SC26304 Antagonist
    SC26304 inhibits the effects of Aldosterone on urinary K+:Na+ ratios and the binding of [3H]Aldosterone to renal cytoplasmic and nuclear receptors.